These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18619180)

  • 1. Polycystic kidney disease: will it become treatable?
    Gross P
    Pol Arch Med Wewn; 2008 May; 118(5):298-301. PubMed ID: 18619180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease.
    Wu M; Wahl PR; Le Hir M; Wackerle-Men Y; Wuthrich RP; Serra AL
    Kidney Blood Press Res; 2007; 30(4):253-9. PubMed ID: 17596700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy for polycystic kidney disease? It's water, stupid!
    Grantham JJ
    J Am Soc Nephrol; 2008 Jan; 19(1):1-7. PubMed ID: 18032792
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic role of sirolimus in non-transplant kidney disease.
    Rangan GK; Nguyen T; Mainra R; Succar L; Schwensen KG; Burgess JS; Ho KO
    Pharmacol Ther; 2009 Aug; 123(2):187-206. PubMed ID: 19374918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycystic kidney disease.
    Fall PJ; Prisant LM
    J Clin Hypertens (Greenwich); 2005 Oct; 7(10):617-9, 625. PubMed ID: 16227765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
    Wu M; Arcaro A; Varga Z; Vogetseder A; Le Hir M; Wüthrich RP; Serra AL
    Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1597-605. PubMed ID: 19776171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.
    Sabbatini M; Russo L; Cappellaio F; Troncone G; Bellevicine C; De Falco V; Buonocore P; Riccio E; Bisesti V; Federico S; Pisani A
    Am J Physiol Renal Physiol; 2014 May; 306(10):F1243-50. PubMed ID: 24647711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications.
    Lieberthal W; Levine JS
    Am J Physiol Renal Physiol; 2012 Jul; 303(2):F180-91. PubMed ID: 22496407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osmoregulation in Polycystic Kidney Disease: Relationship with Cystogenesis and Hypertension.
    Underwood CF; Phillips JK; Hildreth CM
    Ann Nutr Metab; 2018; 72 Suppl 2():33-38. PubMed ID: 29925070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study.
    Soliman AR; Ismail E; Zamil S; Lotfy A
    Transplant Proc; 2009 Nov; 41(9):3639-41. PubMed ID: 19917358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.
    Aihara M; Fujiki H; Mizuguchi H; Hattori K; Ohmoto K; Ishikawa M; Nagano K; Yamamura Y
    J Pharmacol Exp Ther; 2014 May; 349(2):258-67. PubMed ID: 24570071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic advances in the treatment of polycystic kidney disease.
    Riella C; Czarnecki PG; Steinman TI
    Nephron Clin Pract; 2014; 128(3-4):297-302. PubMed ID: 25573484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targets for polycystic kidney disease.
    Wilson PD
    Expert Opin Ther Targets; 2016; 20(1):35-45. PubMed ID: 26328773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis in polycystic kidney disease.
    Goilav B
    Biochim Biophys Acta; 2011 Oct; 1812(10):1272-80. PubMed ID: 21241798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting and therapeutic peptide-based strategies for polycystic kidney disease.
    Wang J; Tripathy N; Chung EJ
    Adv Drug Deliv Rev; 2020; 161-162():176-189. PubMed ID: 32866560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor.
    Sweeney WE; Chen Y; Nakanishi K; Frost P; Avner ED
    Kidney Int; 2000 Jan; 57(1):33-40. PubMed ID: 10620185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging therapies for polycystic kidney disease.
    Gattone VH
    Curr Opin Pharmacol; 2005 Oct; 5(5):535-42. PubMed ID: 16085462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.
    Chapman AB; Johnson A; Gabow PA; Schrier RW
    N Engl J Med; 1990 Oct; 323(16):1091-6. PubMed ID: 2215576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease.
    Jeewandara TM; Ameer OZ; Boyd R; Wyse BF; Underwood CF; Phillips JK
    Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):353-60. PubMed ID: 25676668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in autosomal dominant polycystic kidney disease-2014 and beyond.
    Braun WE
    Cleve Clin J Med; 2014 Sep; 81(9):545-56. PubMed ID: 25183846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.